Literature DB >> 7230985

[Therapy of purulent peritonitis. Documentation of 78 cases and experience with taurolin (author's transl)].

M M Linder, W Ott, G Wesch, O Wicki, M C Marti, G Moser.   

Abstract

From three different surgical departments 78 patients with purulent peritonitis are analyzed according to cause, origin, and extent of peritonitis. Operative therapy is presented. As additional antibacterial therapy the new chemotherapeutic agent, Taurolin, with antiendotoxin-effect is used. The postoperative course (temperature exceeding 38 degrees C, secondary wound healing, day of discharge, and serious complications) is correlated with pre- and intraoperative parameters; for instance, 1. postoperative fever occurs in one half of the patients, more frequently following perforation of stomach and duodenum; 2. every second patient shows secondary wound healing, this happens even more often in peritonitis arising from biliary disease or appendicitis; 3. in 29.5% of the patients serious complications arise, especially in patients with peritonitis originating in stomach, small intestine or large bowel; 4. overall mortality of 11.5% is surpassed in patients with peritonitis originating from small intestine or large bowel. The so-called peritonitis-index (calculated on the basis of pre- and intraoperative factors) shows a significant difference between survivors and patients dying during the postoperative course. In 80% of the 78 patients with purulent peritonitis taurolin was effective as a substitute for the usual antibiotics.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7230985     DOI: 10.1007/bf01266009

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  11 in total

1.  Intraperitoneal lavage and kanamycin for the contaminated abdomen.

Authors:  J L Nelson; J H Kuzman; I Cohn
Journal:  Surg Clin North Am       Date:  1975-12       Impact factor: 2.741

2.  The in vitro and in vivo activity of taurolin against anaerobic pathogenic organisms.

Authors:  M K Browne; G B Leslie; R W Pfirrman; H Brodhage
Journal:  Surg Gynecol Obstet       Date:  1977-12

3.  Wound infections due to Bacteroides fragilis following intestinal surgery.

Authors:  D A Leigh
Journal:  Br J Surg       Date:  1975-05       Impact factor: 6.939

4.  Taurolin, a new chemotherapeutic agent.

Authors:  M K Browne; G B Leslie; R W Pfirrmann
Journal:  J Appl Bacteriol       Date:  1976-12

5.  A rationale for intraperitoneally administered antibiotic therapy.

Authors:  E B Smith
Journal:  Surg Gynecol Obstet       Date:  1976-10

6.  [Intraperitoneal and intravenous tauroflex, without antibiotics in the treatment of 40 cases of peritonitis (author's transl)].

Authors:  G Moser; M C Marti
Journal:  Schweiz Rundsch Med Prax       Date:  1978-03-21

7.  [An index of peritonitis originating in the biliary tract: correlation with the postoperative course (author's transl)].

Authors:  M M Linder; J Götz; W Ott; G Wesch
Journal:  Langenbecks Arch Chir       Date:  1979

8.  C controlled trial of taurolin in established bacterial peritonitis.

Authors:  M K Browne; M MacKenzie; P J Doyle
Journal:  Surg Gynecol Obstet       Date:  1978-05

9.  [Peritonitis in acute appendicitis: prognostic aspects, personal results].

Authors:  G Wesch; M M Linder; W Ott; J Götz
Journal:  Fortschr Med       Date:  1981-02-05

10.  [Antibacterial therapy of purulent peritonitis: a prospective randomized study on the effects of antibiotics and taurolin, a new chemotherapeutic and antiendotoxic agent (author's transl)].

Authors:  M M Linder; W Ott; G Wesch
Journal:  Chir Forum Exp Klin Forsch       Date:  1980
View more
  6 in total

Review 1.  Principles and limitations of operative management of intraabdominal infections.

Authors:  E H Farthmann; U Schöffel
Journal:  World J Surg       Date:  1990 Mar-Apr       Impact factor: 3.352

2.  Efficacy of taurolidine against periodontopathic species--an in vitro study.

Authors:  Sigrun Eick; Sabrina Radakovic; Wolfgang Pfister; Sandor Nietzsche; Anton Sculean
Journal:  Clin Oral Investig       Date:  2011-05-24       Impact factor: 3.573

3.  [In vitro effect of taurolidine on squamous cell carcinoma in the oral cavity].

Authors:  L Petrovic; K A Schlegel; J Ries; J Park; E Diebel; S Schultze-Mosgau; J Wiltfang
Journal:  Mund Kiefer Gesichtschir       Date:  2003-02-14

4.  Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice.

Authors:  Ansgar Michael Chromik; Sebastian Huss; Hayssam Osseili; Adrien Daigeler; Sabine Kersting; Dominique Sülberg; Ulrich Mittelkötter; Thomas Herdegen; Waldemar Uhl; Annette M Müller
Journal:  J Carcinog       Date:  2010-04-16

5.  In vitro activity of taurolidine gel on bacteria associated with periodontitis.

Authors:  Sigrun Eick; Nicoletta Gloor; Cecilia Püls; Jürg Zumbrunn; Anton Sculean
Journal:  Clin Oral Investig       Date:  2015-08-09       Impact factor: 3.573

6.  [Effects and side effects of taurolin in experimental peritonitis in the rat].

Authors:  H Hart; J Seifert; W Brendel
Journal:  Langenbecks Arch Chir       Date:  1986
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.